Starting a biotech company from scratch can be very exciting. Here are some photos from the early days of Viome Life Sciences, 8 years ago. - First day in the office, I used boxes as my desk. - Second day we upgraded with a camping table. - While the offices with carpets were remodeled into labs, we already purchased and tested some instruments in the office. - Within a month, we were testing prototypes of our stool collection kits. - Exactly 5 months from the start, we sold our first product and generated revenue. At that time, the lab was fully manual, but we automated it within a year.
Viome Life Sciences
健康与健身服务
Bellevue,Washington 3,395 位关注者
We're on a mission to decode human biology in order to prevent and reverse chronic diseases, cancers, and aging.
关于我们
Viome Life Sciences was founded in 2016 with a mission to make illness optional by predicting and preventing chronic diseases, cancers, and aging through a deeper understanding of an individual's biology at a molecular level. Viome's Consumer Services (VIOME) provides the industry's only direct-to-consumer healthcare test that analyzes microbial and human gene expressions (mRNA), with technology exclusively licensed from Los Alamos National Lab, in order to provide individuals with health insights and the nutrition they need. Our Health Sciences division focuses on key initiatives including prediction, early diagnostics, prognostics, and precision therapeutics to help people live a disease free life. With our state of the art artificial intelligence platform, we are able to analyze data from the world's largest and richest gene expression database in order to identify the root causes of chronic diseases, cancers, and aging and the mechanisms of action to be able to prevent and reverse them. Prediction: Using advanced AI methods to discover host/microbial biomarkers that predict the risk of developing severe chronic conditions, including cancers. Early Diagnostics: Using host/microbial biomarkers to diagnose severe chronic conditions including cancers at the earliest possible stage. Early diagnosis will enable earlier treatment which often is associated with higher efficacy. Prognostics: Leveraging host/microbial biomarkers to develop companion diagnostics to predict drug effectiveness and further improve responsiveness of patients by proposing AI-guided modulation of the microbiome. Therapeutics: By targeting the root cause of specific chronic diseases with prophylactics or therapeutics such as drugs, monoclonal antibodies, vaccines, phages, or other appropriate modalities.
- 网站
-
https://www.viomelifesciences.com
Viome Life Sciences的外部链接
- 所属行业
- 健康与健身服务
- 规模
- 201-500 人
- 总部
- Bellevue,Washington
- 类型
- 私人持股
- 创立
- 2016
- 领域
- chronic diseases、microbiome、mRNA、Artificial Intelligence、Therapeutics、Metatranscriptomics、RNA、Health Sciences、Life Sciences、Human gene expression和Microbial gene expression
地点
-
主要
205 108th Ave NE
US,Washington,Bellevue,98004
Viome Life Sciences员工
动态
-
Viome Is Partnering with Henry Schein to Provide Better Access to Oral Health Pro? With CancerDetect? "At Henry Schein, we are pleased to deliver the first crucial step in Viome's process for detecting biomarkers associated with oral or throat cancer, marking a significant advancement for Henry Schein's product offerings and dentistry at large in helping to prevent cancer," said Dr.?Bruce Lieberthal, Vice President and Chief Innovation Officer at Henry Schein. "Understanding the importance of early detection and intervention, we're pleased to be able to work with Viome to enhance patient outcomes and usher in a new era for dental and medical professionals. Our vision is to help lead a transformation where oral care prioritizes prevention, focusing on the patient's health and well-being in and outside dental and medical offices. This is a pivotal step in redefining the current standard of care, where early action and prevention lead to a healthier society." For more information please visit?https://viomepro.com?and?https://lnkd.in/eFUrxAA. https://lnkd.in/gbmCnjtJ
-
Another publication by Viome Life Sciences. Subgingival microbiome is likely an important factor in many oral and systemic diseases, but it is challenging to collect subgingival samples. We developed and validated a new collection method, using a swab, that can be performed at home by an individual study participant or customer. Full paper here: https://lnkd.in/guR4zYQD Back to work now.
-
?? Decoding the Human Microbiome with Guruduth Banavar ?? At Viome, we're not just in the business of health; we're redefining it through the lens of individuality, powered by a synergistic blend of biology, human insight, and artificial intelligence. It's our pleasure to unveil a riveting episode on the Impact AI podcast featuring our own Guru Banavar, the visionary founding CTO and Head of Discovery AI. Guru takes us on a journey, exploring the intricacies between AI and the human microbiome. His path to Viome isn’t merely a career choice but a mission to democratize health, ensuring it's tailored and accessible to everyone. Our ethos at Viome is clear: every individual's biochemical uniqueness deserves recognition and respect, and Guru's pioneering work epitomizes this commitment. Navigating the Complexities of AI in Health Guru openly discusses the formidable challenges associated with training AI models on intricate RNA data, a testament to the complex, yet invaluable data amassed from our customers. These obstacles are merely catalysts for innovation, propelling us toward unrivaled accuracy in personalized health interventions. The Genesis of Innovation The transition from a nascent idea to a fully-fledged machine-learning product is a journey rife with complexity. Guru provides a window into Viome’s rigorous planning and development phases, highlighting the technological breakthroughs that enable us to decode the human microbiome on an unprecedented scale. Envisioning Viome's Future Guru's foresight into the next 3-5 years transcends mere expansion; it's about creating a meaningful impact. His guidance for the leaders of AI-driven startups is a clarion call for resilience, ethical AI practices, and an unwavering commitment to making scientific advances accessible to all. Dive into this captivating episode of the Impact AI podcast. Witness firsthand how Guru and the Viome team are charting a revolutionary course in healthcare, positioning the microbiome as the cornerstone of achieving optimal health for every individual. ?? Tune in Now: https://lnkd.in/dbNY6N-t #Viome #ArtificialIntelligence #HumanMicrobiome #PersonalizedHealth #Innovation https://lnkd.in/dbNY6N-t
Decoding the Human Micobiome with Guru Banavar from Viome
pixelscientia.com
-
Big news. Our data from four interventional studies are now published in the American Journal of Lifestyle Medicine; the intervention included only nutritional ingredients (foods and supplements) that can be obtained from a grocery store. Nutritional recommendations are computed and 100% data-driven. These studies are preliminary, and we are currently conducting randomized, placebo-controlled trials for all these indications. https://lnkd.in/gDqzHmHu Thanks to so many people over so many years that have made this possible. If you want to find out more about our precision nutrition platform (Nutrition 2.0), we described it here: https://lnkd.in/g6Z774vi